Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides

In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel) 2024-08, Vol.14 (16), p.1728
Main Authors: Berezina, Tetiana A, Berezin, Oleksandr O, Hoppe, Uta C, Lichtenauer, Michael, Berezin, Alexander E
Format: Article
Language:English
Subjects:
adropin
adverse cardiac remodeling
Biomarkers
circulating biomarkers
Complications and side effects
Health aspects
Heart failure
heart failure with preserved ejection fraction
Insulin resistance
Kidney diseases
Kinases
Natriuretic peptides
Risk factors
Type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c402t-69aa15e305042ff1850402416a2dcff6843a9c833e316deda6d3ec88278f1e893
container_end_page
container_issue 16
container_start_page 1728
container_title Diagnostics (Basel)
container_volume 14
creator Berezina, Tetiana A
Berezin, Oleksandr O
Hoppe, Uta C
Lichtenauer, Michael
Berezin, Alexander E
description In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which have been inconclusive in predicting the transition from asymptomatic adverse cardiac remodeling to HF with preserved ejection fraction (HFpEF). The aim of this study was to elucidate the predictive ability of adropin for HFpEF depending on the circulating levels of NT-proBNP. We prospectively enrolled 561 T2DM patients (glycated hemoglobin < 6.9%) with echocardiographic evidence of structural cardiac abnormalities and left ventricular ejection fractions >50%. All patients underwent B-mode transthoracic echocardiographic and Doppler examinations. Circulating biomarkers, i.e., NT-proBNP and adropin, were assessed at baseline. All individuals were divided into two groups according to the presence of low levels (
doi_str_mv 10.3390/diagnostics14161728
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_50182004c394405ca395fa17bba14888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A807411398</galeid><doaj_id>oai_doaj_org_article_50182004c394405ca395fa17bba14888</doaj_id><sourcerecordid>A807411398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-69aa15e305042ff1850402416a2dcff6843a9c833e316deda6d3ec88278f1e893</originalsourceid><addsrcrecordid>eNptks1u1DAQxyMEolXpEyAhS1y4bOuvJPYJrVrarrRAD-Vsee3JrldJHGynaJ-A18bpltJFtSWPPf7PbzSjKYr3BJ8xJvG5dXrd-5iciYSTitRUvCqOKa7LGedEvH52PypOY9zivCRhgpZviyMmKaaUVMfF77kNfnA9ug1gnUkRzeOuG5LvdGajG9AhoSvt2jEAmmTZDX2W_XJpg-52AyCKLp1eQYKIvkLbujRGtOgtDJCPPiHfoLQBtIR7aOP0-qZTcJk3JbiFITkL8V3xptFthNNHe1L8uPpyd3EzW36_XlzMlzPDMU2zSmpNSmC4xJw2DRHZYpoboKk1TVMJzrQ0gjFgpLJgdWUZGCFoLRoCQrKTYrHnWq-3agiu02GnvHbqweHDWuWKnWlBlZgIijE3THKOS6OZLBtN6tVKEy6EyKzPe9YwrjqwJhcbdHsAPfzp3Uat_b0ihJWMkDoTPj0Sgv85Qkyqc9HkJuoe_BgVw1LWklM5Jfv4n3Trx9DnXk2qWuKK1uU_1VrnClzf-JzYTFA1F7jmOfMD6-wFVd4WOmd8D43L_oMAtg8wwccYoHkqkmA1zaN6YR5z1Ifn_XmK-Tt97A9Wi91z</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097906275</pqid></control><display><type>article</type><title>Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Berezina, Tetiana A ; Berezin, Oleksandr O ; Hoppe, Uta C ; Lichtenauer, Michael ; Berezin, Alexander E</creator><creatorcontrib>Berezina, Tetiana A ; Berezin, Oleksandr O ; Hoppe, Uta C ; Lichtenauer, Michael ; Berezin, Alexander E</creatorcontrib><description>In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which have been inconclusive in predicting the transition from asymptomatic adverse cardiac remodeling to HF with preserved ejection fraction (HFpEF). The aim of this study was to elucidate the predictive ability of adropin for HFpEF depending on the circulating levels of NT-proBNP. We prospectively enrolled 561 T2DM patients (glycated hemoglobin &lt; 6.9%) with echocardiographic evidence of structural cardiac abnormalities and left ventricular ejection fractions &gt;50%. All patients underwent B-mode transthoracic echocardiographic and Doppler examinations. Circulating biomarkers, i.e., NT-proBNP and adropin, were assessed at baseline. All individuals were divided into two groups according to the presence of low levels (&lt;125 pmol/mL; = 162) or elevated levels (≥125 pmol/mL; = 399) of NT-proBNP. Patients with known asymptomatic adverse cardiac remodeling and elevated NT-proBNP were classified as having asymptomatic HFpEF. A multivariate logistic regression showed that low serum levels of adropin (&lt;3.5 ng/mL), its combination with any level of NT-proBNP, and use of SGLT2 inhibitors were independent predictors of HFpEF. However, low levels of adropin significantly increased the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM, even though the concentrations of NT-proBNP were low, while adropin added discriminatory value to all concentrations of NT-proBNP. In conclusion, low levels of adropin significantly increase the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM.</description><identifier>ISSN: 2075-4418</identifier><identifier>EISSN: 2075-4418</identifier><identifier>DOI: 10.3390/diagnostics14161728</identifier><identifier>PMID: 39202216</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>adropin ; adverse cardiac remodeling ; Biomarkers ; circulating biomarkers ; Complications and side effects ; Health aspects ; Heart failure ; heart failure with preserved ejection fraction ; Insulin resistance ; Kidney diseases ; Kinases ; Natriuretic peptides ; Risk factors ; Type 2 diabetes</subject><ispartof>Diagnostics (Basel), 2024-08, Vol.14 (16), p.1728</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c402t-69aa15e305042ff1850402416a2dcff6843a9c833e316deda6d3ec88278f1e893</cites><orcidid>0000-0002-0446-3999</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3097906275/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3097906275?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25733,27903,27904,36991,36992,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39202216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berezina, Tetiana A</creatorcontrib><creatorcontrib>Berezin, Oleksandr O</creatorcontrib><creatorcontrib>Hoppe, Uta C</creatorcontrib><creatorcontrib>Lichtenauer, Michael</creatorcontrib><creatorcontrib>Berezin, Alexander E</creatorcontrib><title>Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides</title><title>Diagnostics (Basel)</title><addtitle>Diagnostics (Basel)</addtitle><description>In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which have been inconclusive in predicting the transition from asymptomatic adverse cardiac remodeling to HF with preserved ejection fraction (HFpEF). The aim of this study was to elucidate the predictive ability of adropin for HFpEF depending on the circulating levels of NT-proBNP. We prospectively enrolled 561 T2DM patients (glycated hemoglobin &lt; 6.9%) with echocardiographic evidence of structural cardiac abnormalities and left ventricular ejection fractions &gt;50%. All patients underwent B-mode transthoracic echocardiographic and Doppler examinations. Circulating biomarkers, i.e., NT-proBNP and adropin, were assessed at baseline. All individuals were divided into two groups according to the presence of low levels (&lt;125 pmol/mL; = 162) or elevated levels (≥125 pmol/mL; = 399) of NT-proBNP. Patients with known asymptomatic adverse cardiac remodeling and elevated NT-proBNP were classified as having asymptomatic HFpEF. A multivariate logistic regression showed that low serum levels of adropin (&lt;3.5 ng/mL), its combination with any level of NT-proBNP, and use of SGLT2 inhibitors were independent predictors of HFpEF. However, low levels of adropin significantly increased the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM, even though the concentrations of NT-proBNP were low, while adropin added discriminatory value to all concentrations of NT-proBNP. In conclusion, low levels of adropin significantly increase the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM.</description><subject>adropin</subject><subject>adverse cardiac remodeling</subject><subject>Biomarkers</subject><subject>circulating biomarkers</subject><subject>Complications and side effects</subject><subject>Health aspects</subject><subject>Heart failure</subject><subject>heart failure with preserved ejection fraction</subject><subject>Insulin resistance</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Natriuretic peptides</subject><subject>Risk factors</subject><subject>Type 2 diabetes</subject><issn>2075-4418</issn><issn>2075-4418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1u1DAQxyMEolXpEyAhS1y4bOuvJPYJrVrarrRAD-Vsee3JrldJHGynaJ-A18bpltJFtSWPPf7PbzSjKYr3BJ8xJvG5dXrd-5iciYSTitRUvCqOKa7LGedEvH52PypOY9zivCRhgpZviyMmKaaUVMfF77kNfnA9ug1gnUkRzeOuG5LvdGajG9AhoSvt2jEAmmTZDX2W_XJpg-52AyCKLp1eQYKIvkLbujRGtOgtDJCPPiHfoLQBtIR7aOP0-qZTcJk3JbiFITkL8V3xptFthNNHe1L8uPpyd3EzW36_XlzMlzPDMU2zSmpNSmC4xJw2DRHZYpoboKk1TVMJzrQ0gjFgpLJgdWUZGCFoLRoCQrKTYrHnWq-3agiu02GnvHbqweHDWuWKnWlBlZgIijE3THKOS6OZLBtN6tVKEy6EyKzPe9YwrjqwJhcbdHsAPfzp3Uat_b0ihJWMkDoTPj0Sgv85Qkyqc9HkJuoe_BgVw1LWklM5Jfv4n3Trx9DnXk2qWuKK1uU_1VrnClzf-JzYTFA1F7jmOfMD6-wFVd4WOmd8D43L_oMAtg8wwccYoHkqkmA1zaN6YR5z1Ifn_XmK-Tt97A9Wi91z</recordid><startdate>20240809</startdate><enddate>20240809</enddate><creator>Berezina, Tetiana A</creator><creator>Berezin, Oleksandr O</creator><creator>Hoppe, Uta C</creator><creator>Lichtenauer, Michael</creator><creator>Berezin, Alexander E</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0446-3999</orcidid></search><sort><creationdate>20240809</creationdate><title>Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides</title><author>Berezina, Tetiana A ; Berezin, Oleksandr O ; Hoppe, Uta C ; Lichtenauer, Michael ; Berezin, Alexander E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-69aa15e305042ff1850402416a2dcff6843a9c833e316deda6d3ec88278f1e893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>adropin</topic><topic>adverse cardiac remodeling</topic><topic>Biomarkers</topic><topic>circulating biomarkers</topic><topic>Complications and side effects</topic><topic>Health aspects</topic><topic>Heart failure</topic><topic>heart failure with preserved ejection fraction</topic><topic>Insulin resistance</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Natriuretic peptides</topic><topic>Risk factors</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berezina, Tetiana A</creatorcontrib><creatorcontrib>Berezin, Oleksandr O</creatorcontrib><creatorcontrib>Hoppe, Uta C</creatorcontrib><creatorcontrib>Lichtenauer, Michael</creatorcontrib><creatorcontrib>Berezin, Alexander E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Diagnostics (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berezina, Tetiana A</au><au>Berezin, Oleksandr O</au><au>Hoppe, Uta C</au><au>Lichtenauer, Michael</au><au>Berezin, Alexander E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides</atitle><jtitle>Diagnostics (Basel)</jtitle><addtitle>Diagnostics (Basel)</addtitle><date>2024-08-09</date><risdate>2024</risdate><volume>14</volume><issue>16</issue><spage>1728</spage><pages>1728-</pages><issn>2075-4418</issn><eissn>2075-4418</eissn><abstract>In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which have been inconclusive in predicting the transition from asymptomatic adverse cardiac remodeling to HF with preserved ejection fraction (HFpEF). The aim of this study was to elucidate the predictive ability of adropin for HFpEF depending on the circulating levels of NT-proBNP. We prospectively enrolled 561 T2DM patients (glycated hemoglobin &lt; 6.9%) with echocardiographic evidence of structural cardiac abnormalities and left ventricular ejection fractions &gt;50%. All patients underwent B-mode transthoracic echocardiographic and Doppler examinations. Circulating biomarkers, i.e., NT-proBNP and adropin, were assessed at baseline. All individuals were divided into two groups according to the presence of low levels (&lt;125 pmol/mL; = 162) or elevated levels (≥125 pmol/mL; = 399) of NT-proBNP. Patients with known asymptomatic adverse cardiac remodeling and elevated NT-proBNP were classified as having asymptomatic HFpEF. A multivariate logistic regression showed that low serum levels of adropin (&lt;3.5 ng/mL), its combination with any level of NT-proBNP, and use of SGLT2 inhibitors were independent predictors of HFpEF. However, low levels of adropin significantly increased the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM, even though the concentrations of NT-proBNP were low, while adropin added discriminatory value to all concentrations of NT-proBNP. In conclusion, low levels of adropin significantly increase the predictive ability of NT-proBNP for asymptomatic HFpEF in patients with T2DM.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39202216</pmid><doi>10.3390/diagnostics14161728</doi><orcidid>https://orcid.org/0000-0002-0446-3999</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2075-4418
ispartof Diagnostics (Basel), 2024-08, Vol.14 (16), p.1728
issn 2075-4418
2075-4418
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_50182004c394405ca395fa17bba14888
source Publicly Available Content (ProQuest); PubMed Central
subjects adropin
adverse cardiac remodeling
Biomarkers
circulating biomarkers
Complications and side effects
Health aspects
Heart failure
heart failure with preserved ejection fraction
Insulin resistance
Kidney diseases
Kinases
Natriuretic peptides
Risk factors
Type 2 diabetes
title Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A23%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adropin%20Predicts%20Asymptomatic%20Heart%20Failure%20in%20Patients%20with%20Type%202%20Diabetes%20Mellitus%20Independent%20of%20the%20Levels%20of%20Natriuretic%20Peptides&rft.jtitle=Diagnostics%20(Basel)&rft.au=Berezina,%20Tetiana%20A&rft.date=2024-08-09&rft.volume=14&rft.issue=16&rft.spage=1728&rft.pages=1728-&rft.issn=2075-4418&rft.eissn=2075-4418&rft_id=info:doi/10.3390/diagnostics14161728&rft_dat=%3Cgale_doaj_%3EA807411398%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c402t-69aa15e305042ff1850402416a2dcff6843a9c833e316deda6d3ec88278f1e893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3097906275&rft_id=info:pmid/39202216&rft_galeid=A807411398&rfr_iscdi=true